This article was originally published in The Tan Sheet
Orajel and cosmetics drove up net sales 20.2% to $77.7 mil. for the third quarter, company says Oct. 26. Net income for the quarter was $1.2 mil., compared to a $6.1 mil. loss in the year-ago period. Nine-month sales totaled $221.7 mil., a 12.6% increase from the prior-year period. Ads for Orajel Ultra Mouth Sore Medicine, which shipped at the end of the quarter, are slated for February 2001 (1"The Tan Sheet" Oct. 9, p. 5)
You may also be interested in...
Del Pharmaceuticals Orajel Ultra Mouth Sore Medicine, which provides "immediate pain relief" while creating a "film-forming gel" to protect canker sores from irritation, will begin appearing on store shelves this month, the company said.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning